ProgressPotentialAndPossibilities

Simon Waslander is the Director of Collaboration, at the CureDAO Alliance for the Acceleration of Clinical Research ( https://www.curedao.org/ ), a community-owned platform for the precision health of the future. CureDAO is creating an open-source platform to discover how millions of factors, like foods, drugs, and supplements affect human health, within a decentralized autonomous organization (DAO), making suffering optional through the creation of a "WordPress of health data". Simon is a native of the Dutch Caribbean island of Aruba, having been born on the island and initially chose to study medicine at the University of Groningen, but then transitioned over to healthcare innovation studies at the University of Maastricht where he wrote his master thesis on the topic of Predictive Healthcare Algorithms. (For information on the discussion segment on AGI, please contact - www.Norn.AI )

Rear Admiral Lorin C. Selby, is the 26th Chief of Naval Research, for the United States Navy ( https://www.navy.mil/Leadership/Flag-Officer-Biographies/Search/Article/2236263/rear-admiral-lorin-selby/ ), a position he assumed command of in May of 2020. The Office of Naval Research (ONR) is an organization within the United States Department of the Navy responsible for the science and technology programs of the U.S. Navy and Marine Corps. Established by Congress in 1946, its mission is to plan, foster, and encourage scientific research to maintain future naval power and preserve national security. Rear Adm. Selby graduated from the University of Virginia with a Bachelor of Science in nuclear engineering and earned his commission through the Navy’s Reserve Officers Training Corps program. He also holds a Master of Science in nuclear engineering and a Nuclear Engineer degree from the Massachusetts Institute of Technology. Rear Adm. Selby’s shipboard tours include USS Puffer (SSN 652), USS Pogy (SSN 647) and USS Connecticut (SSN 22). From July 2004 to May 2007, he commanded USS Greeneville (SSN 772) in Pearl Harbor, Hawaii. During these assignments, Rear Adm. Selby conducted several deployments to the western and northern Pacific, northern Atlantic and Arctic oceans. Ashore, Rear Adm. Selby’s staff assignments include duty as a company officer and instructor at the U.S. Naval Academy; service as the deputy director of the Navy’s liaison office to the U.S. House of Representatives; and duty as the Submarine Platforms and Strategic Programs branch head in the Submarine Warfare Directorate on the Navy Staff. Following selection as an acquisition professional, he served as the program manager for both the Submarine Imaging and Electronic Warfare Systems Program Office (PMS 435) and the Advanced Undersea Systems Program Office (PMS 394). As a flag officer, Rear Adm. Selby served as commander, Naval Surface Warfare Center (NSWC) from October 2014 to August 2016. In this position, he led more than 17,000 scientists, engineers, technicians and support personnel, both civilian and active duty, within eight NSWC divisions located across the country. From June 2016 until May 2020, Rear Adm. Selby served as the Navy’s chief engineer and the Naval Sea Systems Command deputy commander for Ship Design, Integration and Naval Engineering, where he led the engineering and scientific expertise, knowledge and technical authority necessary to design, build, maintain, repair, modernize, certify and dispose of the Navy’s ships, aircraft carriers, submarines and associated combat and weapons systems. Rear Adm. Selby is authorized to wear the Distinguished Service Medal, the Legion of Merit (three awards), Meritorious Service Medal (four awards), the Navy and Marine Corps Commendation Medal (six awards), the Navy and Marine Corps Achievement Medal (three awards) and various unit awards.

Dr. Richard K. Burt MD ( https://astemcelljourney.com/about/drrichardburt/ ) is a Fulbright Scholar, Professor of Medicine at Scripps Health Care, tenured retired Professor of Medicine at Northwestern University where he served as Chief of Immunotherapy and Autoimmune Diseases, and CEO of Genani Biotechnology. Dr. Burt endeavored for thirty-five years, first with animal models and then with some of the world’s first clinical trials, to bring the field of stem cell and cellular therapy to the patient’s bedside. Dr. Burt has published more than 145 mostly first author articles and is the Editor of four medical textbooks. He was the first Autoimmune Committee Chairperson for the International Bone Marrow Transplant Registry (IBMTR) and was the principal investigator of a National Institute of Health (NIH) $10,000,000 multi-center contract to develop stem cell clinical trials for autoimmune diseases. Dr. Burt performed America’s first hematopoietic stem cell transplant (HSCT) for multiple sclerosis (MS), systemic lupus erythematosus (SLE), Crohn’s disease (CD), stiff person syndrome (SPS), and chronic inflammatory demyelinating polyneuropathy (CIDP) and published the world’s first randomized clinical stem cell transplantation trials for systemic sclerosis and multiple sclerosis. Dr. Burt has been awarded Leukemia Scholar of America, the Lupus Foundation of America Fidelitas Award, the Van Bekkum Award by the European Society for Blood and Marrow Transplantation, the Distinguished Clinical Achievement Award by the Clinical Research Forum, and the European Group for Blood and Marrow Transplantation Clinical Achievement Award. Dr. Burt was presented in Vatican City, Rome with the “Keys to the Vatican”, was speaker at the Festival of Thinkers in Leadership in Healthcare in the United Arab Emirates, and chaired the biotechnology session at the Baku Azerbaijan International Humanitarian Forum. Dr. Burt was recognized by Science Illustrated for accomplishing one of the Top 10 medical breakthroughs for the next ten years, and by Scientific American as one of the Top 50 individuals, teams, or organizations for improving humanity and outstanding leadership. His newest book is entitled "Everyday Miracles - Curing Multiple Sclerosis, Scleroderma, and Autoimmune Diseases by Hematopoietic Stem Cell Transplant". ( https://www.amazon.com/Everyday-Miracles-Scleroderma-Autoimmune-Hematopoietic-ebook/dp/B0B9169DNH )

Dr. Victoria Coleman, Ph.D. is the Chief Scientist of the United States Air Force ( https://www.af.mil/About-Us/Biographies/Display/Article/2556343/dr-victoria-coleman/ ), where she serves as the Chief Scientific Adviser to the Secretary of the Air Force, Air Force Chief of Staff, and Chief of Space Operations, providing assessments on a wide range of scientific and technical issues affecting the department’s mission. In this role, Dr. Coleman identifies and analyzes technical issues, bringing them to the attention of department leaders and interacts with other principals, operational commanders, combatant commands, acquisition, and science and technology communities to address cross-organizational issues and provide solutions. Dr. Coleman also interacts with other services and the Office of the Secretary of Defense on issues affecting the Department of the Air Force’s technical enterprise. She serves on the Executive Committee of the Air Force Scientific Advisory Board and is the Principal Science and Technology Representative of the Air Force to the civilian scientific and engineering community and to the public at large. Dr. Coleman is on leave from University of California, Berkeley where since 2016, she has held an academic research appointment at the Berkeley Center for Information Technology in the Interest of Society where she leads science and technology policy on microelectronics and efforts to develop tools for countering digital authoritarianism. Dr. Coleman has more than 35 years of experience in computer science and technology, including as both an academic leader and industry executive. Prior to accepting the role of Chief Scientist of the Air Force, Dr. Coleman served as the 22nd Director of the Defense Advanced Research Projects Agency (DARPA) where she oversaw a large suite of disruptive and innovative programs as well as leadership of the Microsystems Exploratory Council. Before DARPA, she served as the Chief Executive Officer of Atlas AI P.B.C, a Silicon Valley start-up that brings world-class artificial intelligence solutions to sustainable development. By combining satellite data with other data sets, Atlas AI’s proprietary deep-learning models create actionable insights for governments, non-governmental organizations and commercial companies. Dr. Coleman began her academic career in 1988 as a lecturer in computer science at Royal Holloway College, University of London, United Kingdom. She subsequently joined Queen Mary College, University of London, as a reader in computer science. There, she taught undergraduate and graduate courses in computer science, created a Master of Science program in Dependable Computer Systems and supervised Doctor of Philosophy students. In 1998, Dr. Coleman became the founding director of the System Design Laboratory at SRI International. The lab conducted research in trustworthy systems and cyber security. The programs she directed won support from DARPA. She also participated in the creation of the technologies leading to the spinout of Siri prior to its acquisition by Apple. She worked alongside the newly-formed Department of Homeland Security, creating the department’s cyber security agenda and becoming the founding Director of the DHS Cyber Security Research and Development Center. In 2004, Dr. Coleman became the Director of the Trust and Manageability Lab in the Corporate Technology Group of Intel and began serving as a member of Santa Clara University’s Computer Science and Engineering Department’s Advisory Board. In 2006, she became the Vice President of the Computer Science Laboratory at Samsung. In 2010, she took the position of Vice President of Software Engineering at Hewlett-Packard. In 2011, she became Nokia’s Vice President of Emerging Platforms. Dr. Coleman served as the Vice President of Engineering for Multi-Device UX Platforms for Yahoo in 2013, and then took the position of Senior Vice President of Research and Design at Harman International Industries Infotainment Business Unit. She then served as the Senior Vice President and Chief Technology Officer of Connected Home Business for Technicolor. Beginning in 2016, Dr. Coleman served as the Chief Technology Officer of Wikimedia Foundation, the non-profit that supports Wikipedia, the world’s fifth most visited website. During this time, Dr. Coleman also served as a member of the Defense Science Board, where she provided independent advice to the Secretary of Defense, USD(R&E), and the Chairman of the Joint Chiefs of Staff. She was a member of Lockheed Martin’s Technology Advisory Group, the Airbus Star Program and continued her work on the Santa Clara University Computer Science and Engineering Advisory Board. She served on the Board of Directors of the Public Library of Science.

Dr. Stuart Minchin, Ph.D. is the Director General of the Pacific Community ( SPC - https://www.spc.int/about-us/director-general ) which is the largest intergovernmental organization in the Pacific and serves as a science and technology for development organization owned by the 26 Member countries and territories in the Pacific region. SPC’s 650 member staff deliver services and scientific advice to the Pacific across the domains of Oceans, Islands and People, and has deep expertise in food security, water resources, fisheries, disasters, energy, maritime, health, statistics, education, human rights, social development and natural resources. Dr. Minchin previously served as the Chief of the Environmental Geoscience Division of Geoscience Australia, and has an extensive background in the management and modelling of environmental data and the online delivery of data, modelling and reporting tools for improved natural resource management. He has a long track record of conceiving, developing and delivering transformational and innovative projects in the Environmental and Natural Resource Management domains. Dr. Minchin has represented Australia in key international forums and was Australia’s Principal Delegate to both the UN Global Geospatial Information Management Group of Experts (UNGGIM) and the Intergovernmental Group on Earth Observations (GEO). Dr. Minchin has previously been responsible for the Environmental Observation and Landscape Science (EOLS) research program in CSIRO and prior to that was a Principal Scientist with the Victorian Department of Sustainability and Environment. Dr. Minchin has a PhD in Aquatic/Environmental Chemistry, from Monash University, where he also did his undergraduate work in Chemistry achieving a BSc (Hons). He also holds a BSc (Aquatic Science), Aquatic Chemistry and Aquatic Biology from Deakin University.

Judge Karen Friedman is the Director of Criminal Justice Innovation, Development and Engagement, at the Bureau of Justice Assistance, Office of Justice Programs, at the U.S. Department of Justice ( https://bja.ojp.gov/bio/karen-friedman ), a position she was appointed to by President Biden on January 3rd of 2022. The Bureau of Justice Assistance (BJA) was created in 1984 to reduce violent crime, create safer communities, and reform the U.S. criminal justice system, and helps America’s state, local, and tribal jurisdictions reduce and prevent crime, reduce recidivism, and promote a fair and safe criminal justice system. BJA focuses its programmatic and policy efforts on providing a wide range of resources, including training and technical assistance, to law enforcement, courts, corrections, treatment, reentry, justice information sharing, and community-based partners, to address chronic and emerging criminal justice challenges nationwide. Judge Friedman comes to this important role after serving over 20 years as a member of the Maryland Judiciary sitting in Baltimore. In that capacity she served on every level of trial court and completed her service on the Baltimore City Circuit Court, the highest trial court in the state. She headed Baltimore’s drug treatment court and sat on the judiciary’s Equal Justice Commission’s sentencing subcommittee. Judge Friedman is known in Baltimore for her expertise on the intersection of criminal justice with behavioral health, as well as for her innovative approach to sentencing and probation. She is looking forward to using the wealth of knowledge gained on the bench in Baltimore to help improve the lives of those affected by the criminal justice system. Judge Friedman earned her undergraduate degree in political science from the University of Maryland, Baltimore County, and her law degree from the University of Maryland School of Law. She is also the host of the Justice Today Podcast, the official podcast of the Office of Justice Programs

Dr. David A. Tarantino, Jr., MD, MPH; CAPT MC (FS/FMF) Ret., is the Chief Medical Officer, at the United States Customs and Border Protection ( CBP - https://www.cbp.gov/ ), the largest federal law enforcement agency of the United States Department of Homeland Security ( DHS - https://www.dhs.gov/ ), and the country's primary border control organization. It is charged with regulating and facilitating international trade, collecting import duties, and enforcing U.S. regulations, including trade, customs, and immigration. Dr. Tarantino has previously served as Adjunct Assistant Professor, Global Health Division, Preventive Medicine & Biostatistics, Uniformed Services University of the Health Sciences (USUHS), as Director for Civil-Military Medical Affairs in the Office of the Secretary of Defense for Health Affairs in the U.S. Department of Defense, and as a family practice physician/flight surgeon in the U.S. Navy. Dr. Tarantino served as Medical Advisor to the Coalition Provisional Authority/Ministry of Health and then Senior Consultant for the U.S. Mission Baghdad to the Interim Iraqi Government Ministry of Health. He had a significant leadership role in reestablishing the Iraqi Ministry of Health and health care for all Iraqis and served as the principal US Government advisor to the new Iraqi Minister of Health. Dr. Tarantino's military career has been distinguished by multiple challenging overseas and operational assignments, including medical and humanitarian missions in Iraq, Alaska, Haiti, Guyana, Tanzania, Cambodia, Estonia and several Pacific Rim nations. He served as medical director and team physician for a challenging deployment to Turkey in the aftermath of their massive 1999 earthquake, providing emergent medical/surgical care in an austere and chaotic setting. Dr. Tarantino has a B. A. in Human Biology from Stanford University, an M.D. from Georgetown University School of Medicine, a Residency in Family Medicine at Bremerton Naval Hospital, an M.P.H. and Preventive Medicine Residency at the USUHS, and an International Diploma in Humanitarian Assistance, from the Institute of International Humanitarian Affairs (IIHA).

Dr. Tobias Reichmuth, Ph.D. is Founding Partner at Maximon ( https://www.maximon.com/ ), The Longevity Company Builder, which empowers entrepreneurs to build impactful, science-based and scalable companies providing healthy aging and rejuvenation solutions. Maximon recently announced the launch of their 100 million CHF Longevity Co-Investment Fund, which will be looking to invest up to CHF 10 million per company, which allows them to finance up to 10-12 start-ups in this fast growing industry over the next four years. In 2020, Dr. Reichmuth launched the Longevity Investors Conference together with Marc P. Bernegger, another Maximon Founding Partner. Dr. Reichmuth previously founded the climate-change infrastructure fund / asset management company SUSI Partners AG , where he spent over a decade specializing in infrastructure investments in the context of energy transition (renewable energy, energy efficiency, energy storage solutions) and invested more than one billion Swiss francs. Dr. Reichmuth is also co-founder of Crypto AG Finance (a financial technology holding company based in Zug), The Singularity Group (an asset manager in Zug) and the Crypto Finance Conference, which he initiated. He is also well known for his participation as one of the “lions” in the TV program, The Lion's Cave Switzerland on TV24 . Earlier on in his career Dr. Reichmuth worked as a director for an international foundation and consulted Fortune-500 companies. He worked as a strategy consultant with The Boston Consulting Group, co-authored a standard reference for investors on sustainable investments, and is a member of the German Economic Council. Dr. Reichmuth has a Ph.D. in Business Administration from European Business School Oestrich-Winkel.

Professor Dr. Edward (Eddie) Holmes, Ph.D. ( https://www.sydney.edu.au/science/about/our-people/academic-staff/edward-holmes.html ) is an evolutionary biologist distinguished for his work on the emergence and evolution of viruses and over the years of his career he has used genomic and phylogenetic approaches to reveal the major mechanisms of virus evolution and determined the genetic and epidemiological processes that explain how viruses jump species boundaries and spread in new hosts. Dr. Holmes work has revealed the origin, evolution and molecular epidemiology of important human pathogens including influenza, HIV and dengue, and enabled more accurate assessments of what types of virus are most likely to emerge in human populations and whether they will evolve human-to-human transmission. His recent research has provided fundamental insights into the breadth and biodiversity of the viral world and has additionally studied the emergence and spread of such pathogens as SARS-CoV-2, hepatitis C virus, myxoma virus, Rabbit Hemorrhagic Disease Virus and Yersinia pestis, among many others. Dr. Holmes is currently a Professor in the Sydney Institute for Infectious Diseases, School of Life and Environmental Sciences and Sydney Medical School at the University of Sydney. In 2003 he was awarded the Scientific Medal of the Zoological Society of London and in 2015 was elected a Fellow of the Australian Academy of Science. Dr. Holmes previous appointments include the Verne M. Willaman Chair in the Life Sciences at the Pennsylvania State University, USA, and Affiliate Member of the Fogarty International Centre (2005-2012), National Institutes of Health, USA. From 1999-2004 he was Fellow of New College, Oxford. He is also an Honorary Visiting Professor at Fudan University, Shanghai. In 2021 he received the (Australian) Prime Minister's Prize for Science. Dr. Holmes is the author of 691 peer-reviewed papers and two books including The Evolution and Emergence of RNA Viruses (Oxford University Press, 2009).

Dr. Loren Matheson, Ph.D. is a Portfolio Manager at the Center For Security Science, at Defence Research and Development Canada ( DRDC - https://www.canada.ca/en/defence-research-development.html ), which is a special operating agency of the Department of National Defence, whose purpose is to provide the Canadian Armed Forces, other government departments, and public safety and national security communities with knowledge and technology. With a focus on the chemical and biological sciences at DRDC, Dr. Matheson develops and leads safety and security R&D projects with government partners, industry and academia. In addition, she spearheaded an effort to establish a virtual symposium series, developed communications products to explain their program to national and international partners, and helped established a science communication position. Dr. Matheson previously served as both a senior science advisor within the Office of the Chief Science Operating Officer, and National Manager, Plant Health Research and Strategies, at the Canadian Food Inspection Agency. After 10 years consulting as a grants facilitator in clinical research, Dr. Matheson moved to the public service to pursue interests in science policy and security science. Dr. Matheson holds a Ph.D. in Biochemistry from the University of Ottawa and spent her post-doctoral time at the University of Saskatchewan, working on cell and molecular biology, as well as at the Royal University Hospital Canadian Arthritis Network focusing on pediatric rheumatology. Dr. Matheson is a 2022 Women in Defence and Security (WiDS) Emerging Leader ( https://www.wids.ca/cms/Emerging-Leaders ) for her exceptional work improving communications within DRDC’s Center for Security Science in her first year as a Defence Scientist. PLEASE NOTE - the views and opinions expressed are those of the individual and should not be interpreted as representing official policies of the organizations or countries. CLARIFICATION: During recording Dr. Matheson alluded to the Canadian Safety and Security Program (CSSP) targeting proposals from Canadian government scientists. Please note that while CSSP does fund government science, the CSSP also funds research and development through academia and industry. The goal of the program is to allow Canadian government departments to meet their safety and security requirement with science and technology solutions in collaboration with industry and/or academia. Links of interest: - Link to Science diplomacy for plant health | Nature Plants - https://www.nature.com/articles/s41477-020-0744-x - Link to the Canadian Safety and Security Program (science.gc.ca) - https://science.gc.ca/site/science/en/canadian-safety-and-security-program - Link to the paper about a Divergent SARS-CoV-2 variant emerges in white-tailed deer with deer-to-human transmission | Nature Microbiology - https://www.nature.com/articles/s41564-022-01268-9

Prof. Dr. Tony Donne, Ph.D. is Program Manager (CEO) of the EUROfusion ( https://www.euro-fusion.org/ ) research consortium, a European consortium of 30 national fusion research institutes, in 26 EU countries, plus Switzerland and Ukraine, where he coordinates the work of over 4,000 scientists and engineers. Dr. Donne trained as a physicist, obtaining his Masters in Experimental Physics at Utrecht University, his Ph.D. degree at the Free University of Amsterdam for work in the field of nuclear physics, and moved into fusion research right afterwards and has devoted a substantial part of his scientific career to the design and use of plasma diagnostics in a large range of fusion devices. Prior to EUROfusion, Dr. Donne was head of the Fusion Physics Division at the Dutch Institute for Fundamental Energy Research (DIFFER) and responsible for the coordination of the nuclear fusion research in the Netherlands, where he coordinated Dutch fusion research as Director of fusion science and Acting Director. Dr. Donne has also served as Professor in Diagnostics and Heating of Fusion Plasmas at Eindhoven University of Technology, Director of the Dutch-Russian Centre of Excellence on Fusion Physics and Technology, as well as Program Director of the ITER (International Thermonuclear Experimental Reactor) -Netherlands consortium, and chair of the Coordination Committee of the International Tokamak Physics Activity under the auspices of the ITER project. Dr. Donne has published about 185 papers in peer-reviewed journals and more than 350 conference proceedings.

Dr. Seemay Chou, Ph.D. is the Co-Founder, CEO, and Board Member of Arcadia Science ( https://www.arcadia.science/ ), a research and development company focusing on under researched areas in biology, with a specific focus on novel model organisms that haven't been traditionally studied in the lab. The goals of Arcadia Science are to unlock the knowledge and ingenuity contained within a wide range of diverse species, uncover how evolution has solved limitless problems, and through revealing this untapped biological innovation, generate new technologies and products. Dr. Chou is also the co-founder of Trove Biolabs ( https://www.trovebiolabs.com/ ), a startup focused on harnessing novel molecules found in tick saliva for skin therapies. Dr. Chou joined Arcadia from UCSF where she was an Assistant Professor in Biochemistry and Biophysics. Dr. Chou received a Ph.D. in Molecular Cell Biology from UC Berkeley, and her Bachelor of Science (B.S.) in Cell/Cellular and Molecular Biology from University of Texas at Austin.

H. E. President Surangel S. Whipps, Jr. is the 10th President of the Republic of Palau ( https://www.palaugov.pw/executive-branch/president/ ). President Whipps was formerly a two-term Senator having served in the 8th and 9th Olbiil Era Kelulau (OEK, Palau National Congress) from 2009 through 2016. His Senate report card maintains his reputable record in policy making to promote and protect the best interests of Palauans, including: conducting more than 100 oversight hearings to promote transparency and accountability in delivery of government services, spearheading the first bill introduced in the 9th OEK that became law to increase the minimum wage since its enactment in 1997, and most recently, balancing Palau’s focus on developing and promoting human resources and fostering their economy, while striking a balance in the protection of the environment, putting the Palauan people first. Prior to his career in politics, President Whipps had over 30 years of private sector experience managing one of the largest growing companies in Palau. As CEO and president of the Surangel and Sons Company, he led the expansion from a one floor store with 50 employees, to a diversified company employing over six-hundred people. President Whipps grew up in a family business that started with his parents improvising to sustain their living by opening a restaurant, fishing and selling their catch, taking tourists out to the rock islands and diving, and selling goods out of their house. President Whipps' experience is combined with his formal background earning a bachelor’s degree in Business Administration in economics from Andrews University in Michigan and an MBA from Anderson Graduate School of Management at University of California, Los Angeles (UCLA). President Whippsʻ slogan - “A Kot a Rechand er Belau” (Palauan People First) actually originated from his father, who was active in the Save Palau movement to protect Palauʻs marine resources, and who ran for congress many times before being elected. In response to unfair treatment in the workplace, lack of career opportunities for Palauans, challenges hindering young Palauan entrepreneurs, and the unchecked exploitation of Palauʻs national resources, the slogan represented conviction that Palauans must reap the opportunities Palau has to offer, and the commitment to push for the improved welfare of Palauans to be foremost in their country by their government.

Dr. Jennifer A. Fogarty, Ph.D. ( https://www.bcm.edu/people-search/jennifer-fogarty-100936) is the Chief Scientific Officer for the Translational Research Institute for Space Health ( TRISH - https://www.bcm.edu/academic-centers/space-medicine/translational-research-institute ) at Baylor College of Medicine, and the Director of the Applied Health and Performance at Sophic Synergistics LLC. As Chief Scientist of TRISH, Dr. Fogarty leads an innovative and high-risk research and technology development portfolio to address the most challenging human health and performance risks of space exploration. At Sophic Synergistics, which is a women-owned and women-led Human Centered Design firm specializing in integrating human factors engineering and human health and performance into a business model, Dr. Fogarty’s Division focuses on developing and expanding the application of medical technologies for use in remote medicine, telemedicine, and home healthcare. In both roles, Dr. Fogarty’s goal is to increase access to high quality healthcare and empower patients and medical providers by incorporating precision medicine and cutting-edge science and technology with actionable data both in space and on Earth. Dr. Fogarty has over twenty years of experience in medical physiology and extreme environments and was the NASA Human Research Program Chief Scientist. Her approach prioritizes communication and collaboration with industry academia, government and commercial spaceflight programs, and international partners. She values and seeks collaborations with external institutions and government agencies to assess fundamental and mechanistic discoveries as well as innovative prevention and treatment strategies for application to preserve health and performance. Dr. Fogarty has a Ph.D. in Medical Physiology from Texas A&M University School of Medicine and a B.S. in Biology from Stockton University . She is currently an Assistant Professor in the Department of Medicine at Baylor College of Medicine, an editor of the Fundamentals of Aerospace Medicine 4th and 5th edition, and associate editor for the journal npj Microgravity.

Dr. Svitlana Volkova, Ph.D. (https://www.pnnl.gov/people/svitlana-volkova) is Chief Scientist, Decision Intelligence and Analytics, National Security Directorate, Pacific Northwest National Laboratory (PNNL), which is one of the United States Department of Energy national laboratories, managed by the Department of Energy's (DOE) Office of Science. Dr. Volkova is a recognized leader in the field of computational social science and computational linguistics and her scientific contributions and publication profile cover a range of topics on applied machine learning, deep learning, natural language processing, and social media analytics. Dr. Volkova’s research focuses on understanding, predicting, and explaining human behavior, interactions, and real-world events from open-source social data and her approaches help advance effective decision making and reasoning about extreme volumes of dynamic, multilingual, multimodal, and diverse real-world unstructured data. Dr. Volkova has a Ph.D. in Computer Science from Johns Hopkins University, Center for Language and Speech Processing, and an M.S. in Computer Science, from Kansas State University.

Dr. Egbert Edelbroek, Ph.D. is the CEO & Founder of SpaceBorn United ( https://spacebornunited.com/ ), a research and mission design company focused on researching optimal conditions for human reproduction in space, with a focus on novel assisted reproductive technologies. Dr. Edelbroek is passionate about accelerating space life science research, helping humanity to become a multi-planetary species. His interest in space exploration accelerated shortly after he became a sperm donor in 2010 and when learned all about assisted reproductive technologies. This inspired him to explore options to re-engineer existing IVF technology for application in space. Dr. Edelbroek earned his Ph.D. studying courage development in organizations from Radboud University, a Master's degreein neuro-linguistic programming & coaching from IEP Nijmegen, and a Master's degree in organizational sciences from Tilburg University. Dr. Edelbroek enjoys innovating and exploring boundaries by connecting domains and experts that usually remain separated in order to expand the human comfort zone.

Dr. Renée Deehan, Ph.D. is the VP of Science & Artificial Intelligence at InsideTracker ( https://www.insidetracker.com/ ), and leads a science team that builds and mines the world's largest data set of blood, DNA, fitness tracking and phenotypic data from healthy people, creating evidence-based solutions that are simple, clear, and actionable. Dr. Deehan has spent her career working in the precision medicine and personalized nutrition domains, previously serving as the VP of Computational Biology & Translational Informatics at QuartzBio and as the VP of Biology and Bioinformatics at PatientsLikeMe, the world’s largest integrated community, health management, and real-world data platform. At PatientsLikeMe, Dr. Deehan was responsible for data and knowledge engineering, AI/machine-learning, and translational biology functions that drove infrastructure and consumer & business product development. She was also the Principal Investigator for the DigitalMe Ignite program, which collected longitudinal blood and patient-generated health data from over 5,000 at-home site visits from over 2,000 participants and was able to generate over 2 Million data points from the DigitalMe program. Dr. Deehan also designed and cross-functionally implemented the first generation of an “advanced research platform”, capable of integrating survey and omics data for biomarker analysis, including ensemble-based machine-learning pipelines. Additionally, they developed an outsourced pipeline to support their wet-lab omics needs (DNA/RNAseq, proteomics, immune sequencing/antibody repertoire analysis, metabolomics, methylomics). Dr. Deehan has a Ph.D in Molecular and Cell Biology from University of California, Berkeley and a BSE in Bioengineering from University of Pennsylvania. Dr. Deehan LinkedIn - https://www.linkedin.com/in/ren%C3%A9e-deehan-747b471/

Dr. David A. Markowitz, Ph.D. ( https://www.markowitz.bio/ ) is a Program Manager at the Intelligence Advanced Research Projects Activity ( IARPA - https://www.iarpa.gov/ ) which is an organization that invests in high-risk, high-payoff research programs to tackle some of the most difficult challenges of the agencies and disciplines in the U.S. Intelligence Community (IC). IARPA’s mission is to push the boundaries of science to develop solutions that empower the U.S. IC to do its work better and more efficiently for national security. IARPA does not have an operational mission and does not deploy technologies directly to the field, but instead, they facilitate the transition of research results to IC customers for operational application. Currently, Dr. Markowitz leads three research programs at the intersection between biology, engineering, and computing. These programs are: FELIX, which is revolutionizing the field of bio-surveillance with new experimental and computational tools for detecting genetic engineering in complex biological samples; MIST, which is developing compact and inexpensive DNA data storage devices to address rapidly growing enterprise storage needs; and MICrONS, which is guiding the development of next-generation machine learning algorithms by reverse-engineering the computations performed by mammalian neocortex. Previously, as a researcher in neuroscience, Dr. Markowitz published first-author papers on neural computation, the neural circuit basis of cognition in primates, and neural decoding strategies for brain-machine interfaces. Dr. Markowitz received his Ph.D. in molecular biology and neuroscience from Princeton University and his Bachelor’s degree in management science from Massachusetts Institute of Technology (MIT). He was a DOE Computational Science Graduate Fellow and a Swartz Foundation Postdoctoral Fellow in Computational Neuroscience. Dr. Markowitz is a recipient of the 2019 Presidential Early Career Award for Scientists and Engineers.

Dr. Margaret "Peggy" Hamburg, MD is an internationally recognized leader in public health and medicine, who currently serves as chair of the Nuclear Threat Initiative’s (NTI) bio Advisory Group ( https://www.nti.org/about/people/margaret-hamburg-md/ ), where she has also served as founding vice president and senior scientist. She also currently holds a role as Commissioner on the Bipartisan Commission on Biodefense ( https://biodefensecommission.org/teams/margaret-a-hamburg/ ). Dr. Hamburg previously served as foreign secretary of the National Academy of Medicine and is a former Commissioner of the U.S. Food and Drug Administration (FDA), having served for almost six years where she was well known for advancing regulatory science, modernizing regulatory pathways, and globalizing the agency. Previous government positions include Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services, Health Commissioner for New York City, and Assistant Director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. In her role, as Foreign Secretary of the National Academy of Medicine, the health arm of the National Academy of Sciences, Engineering and Medicine, Dr. Hamburg served as senior advisor on international matters and was the liaison with other Academies of Medicine around the world. She is an elected member of the Council on Foreign Relations and the National Academy of Medicine. Dr. Hamburg currently sits on the boards of the Commonwealth Fund, the Simons Foundation, the Urban Institute, the Global Alliance for Vaccines and Immunization, the Parker Institute for Cancer Immunotherapy and the American Museum of Natural History. She is chair of the Joint Coordinating Group for the Coalition for Epidemic Preparedness and Innovation, and a member of the Harvard University Global Advisory Council, the Global Health Scientific Advisory Committee for the Gates Foundation, the Harvard Medical School Board of Fellows, and the World Dementia Council. Dr. Hamburg earned her B.A. from Harvard College, her M.D. from Harvard Medical School and completed her medical residency at Weill Cornell Medical Center. She is the recipient of multiple honorary degrees and numerous awards.

Dr. Sharon K. Inouye is the Director of the Aging Brain Center at the Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife in Boston, Massachusetts ( https://www.marcusinstituteforaging.org/scientists/team-profiles-and-bios/sharon-k-inouye-md-mph ). Dr. Inouye has an M.D., from University of California San Francisco and M.P.H. from Yale and currently holds the Milton and Shirley F. Levy Family Chair and is a Professor of Medicine at Harvard Medical School (Beth Israel Deaconess Medical Center). Her research focuses on delirium and functional decline in hospitalized older patients, resulting in more than 300 peer-reviewed original articles to date. Dr. Inouye is the principal investigator of the Successful Aging after Elective Surgery (SAGES) study, an $11 million Program Project on delirium funded by the National Institute on Aging whose purpose is to examine the interface of delirium and dementia, whether delirium alters the course of dementia, and whether delirium leads to longstanding cognitive impairment and pathologic changes in the brain. Dr. Inouye developed and validated the Confusion Assessment Method (CAM), the most widely-used instrument for the identification of delirium. She conceptualized the multi-factorial model for delirium, which focuses on identification of predisposing and precipitating factors for delirium and her work involves translating theories of clinical investigation into practical applications that directly improve the quality of life for older adults. Dr. Inouye has also developed the Hospital Elder Life Program (HELP), a multi-component intervention strategy designed to prevent delirium by targeting six delirium risk factors. HELP was successful in reducing delirium by 40 percent and was published in a landmark study in the New England Journal of Medicine. This study was the first to show that a substantial proportion of delirium is preventable. Additionally, HELP has been shown to reduce falls, functional decline, and hospital costs, and to improve patient, family, and nursing satisfaction. The HELP program has been adopted by hundreds of hospitals worldwide. Dr. Inouye has been awarded many of the highest accolades in her field, including being elected to the Institute of Medicine of the National Academies. Important Links Delirium Central—for more information about delirium for families, caregivers, and healthcare professionals - https://www.deliriumcentral.org/ HELP—the Hospital Elder Life Program - https://help.agscocare.org/ National Academy of Medicine report: Global Roadmap for Healthy Longevity - https://nam.edu/initiatives/grand-challenge-healthy-longevity/global-roadmap-for-healthy-longevity/

Dr. Michael Hufford, Ph.D. is the Co-Founder and the Chief Executive Officer of LyGenesis ( https://www.lygenesis.com/ ), a clinical-stage cell therapy company that transforms patient’s lymph nodes into bioreactors capable of growing functioning ectopic organs. He also serves as the Interim CEO of Morphoceuticals ( https://www.morphoceuticals.com/ ) a company focused on modifying electric potentials in cells and tissues for a variety of applications in regenerative medicine, from improving amputation stump health and limb regeneration, to organogenesis, to creating a bioelectric atlas where numerous disease indications may be corrected. Dr. Hufford also serves as a scientific advisor to Juvenescence ( https://juvlabs.com/ ) a biotech holding company that develops therapies and products to modify aging and help people live longer. An entrepreneur and drug developer, Dr. Hufford has over 20 years of experience in the development and FDA regulatory approval of small molecules (Cypress Bioscience), biologics (Amylin Pharmaceuticals), as well as drug delivery technologies (e-Nicotine Technology). He has designed and executed clinical trials and drug development programs across a wide variety of therapeutic areas, from orphan metabolic diseases to psychiatric and oncology indications. His experience in- and out-licensing pre-clinical and clinical stage assets, executing corporate partnering deals, and in investor relations, has helped him to raise public, private, and angel-back financing for his companies. His philanthropic work includes co-founding and serving as the CEO of Harm Reduction Therapeutics, Inc. ( https://www.harmreductiontherapeutics.org/ ), a nonprofit pharmaceutical company developing low-cost over-the-counter intra-nasal naloxone in the US to help prevent opioid overdose deaths. Dr. Hufford earned his undergraduate degree with distinction from Purdue University, and his master’s and doctoral degrees in Clinical Psychology from the University of Pittsburgh, before completing a Research and Clinical Fellowship in the Department of Psychiatry at Harvard Medical School. He is an award-winning lecturer, and the author of more than 100 scientific publications, presentations, and OpEds, with multiple issued and pending patents.

Dr. Brett Kagan, Ph.D. is the Chief Scientific Officer at Cortical Labs ( https://corticallabs.com/ ), a biological computing startup putting live neurons into chips to revolutionize computing and help usher in the post-silicon age. Potential applications for the unique organic-digital convergence tools that Cortical Labs is working on are quite broad including: novel ex-vivo models for drug screening in CNS conditions such as epilepsy and dementia; a deeper understanding about how our brains organize activity and learn; inspiration for new machine learning methods; and ultimately tapping the inherent intelligence of living neurons, for their superior computing power and low energy consumption, for the creation of true neuromorphic computing. Dr. Kagan obtained a Bachelors of Psychology from Bond University, a Masters of Neuroscience from the The University of Queensland, and a Ph.D., focused on Cell Therapy for Neonatal Brain, from the University of Melbourne.

Dee Siren ( https://mrssiren.com/ ) is a veteran adult entertainment professional who wears many titles within the industry including as a director, producer, sex educator, performer, content creator, and CEO of SirenXXXStudios ( https://sirenxxxstudios.com/ ) . Dee attended the University of Texas in San Antonio, earning a degree in Interdisciplinary Studies and a certification in Education and began a career in teaching before segueing into the adult entertainment industry. Dee is also a certified sex educator by the American College of Sexologists and currently offers life coaching and career consultation through Intimate Purpose LLC ( MyKarmaSutra.com ), where she uses her knowledge to assist others in finding their new path to happier, healthier, and productive relationships. Dee is also a brand ambassador for the ePlay streaming service and as a core team member / production partner at Vicewrld DAO ( https://vicewrld.com/ ) which will focus on producing video and image-based content and, in the future, full immersion Metaverse AR / VR-based content.

John Sherman is the Chief Information Officer (DoD CIO) at the U.S. Department of Defense ( https://www.defense.gov/About/Biographies/Biography/Article/2881098/john-sherman/ ), a role he was sworn in on December 17, 2021. In this role he is the principal advisor to the Secretary of Defense for Information Management / Information Technology (IT) and Information Assurance, as well as non-intelligence space systems; critical satellite communications, navigation, and timing programs; spectrum; and telecommunications matters. ( https://dodcio.defense.gov/about-dod-cio/ ) Prior to assuming his duties, Mr. Sherman served as the Acting DoD CIO and Principal Deputy, DoD CIO from June 2020 to September 2021. Before joining the Department, Mr. Sherman served as the Intelligence Community (IC) CIO from 2017-2020. In this position he was involved in driving and coordinating IT modernization among 17 agencies, leading major advancements to the IC’s cloud computing, cybersecurity, and interoperability capabilities. He built long-term commitment to these priorities among stakeholders, both in government and industry, and ensured that the IC would remain a leader in each of these areas. Prior to his tour as the IC CIO, Mr. Sherman served from 2014-2017 as the Deputy Director of the Central Intelligence Agency’s (CIA’s) Open Source Enterprise (OSE), where he helped transform Open Source Intelligence, leveraging new technologies and interagency partnerships to enhance the growing OSE mission. He previously served for seven years in several senior executive positions at the National Geospatial-Intelligence Agency (NGA), where he led organizations involved in analysis, collection, homeland security, organizational strategy, and international affairs. Earlier, he served as the Principal Deputy National Intelligence Officer for Military Issues on the National Intelligence Council, and as a White House Situation Room duty officer. Mr. Sherman began his IC career in 1997 as an imagery analyst. Mr. Sherman is a 1992 Distinguished Military Graduate of Texas A&M University where he commanded the Corps of Cadets and received a Bachelor of Arts degree in History. He also earned a Master’s degree in Public Administration from the University of Houston. Following graduation from Texas A&M, he served as an Air Defense Officer in the 24th Infantry Division. He is a graduate of the DoD CAPSTONE course, the “Leading the IC” course, and the CIA Director’s Seminar. Mr. Sherman's awards include the Distinguished and Meritorious Presidential Rank, the DIA Director’s Award, the CIA Intelligence Medal of Merit, the Secretary of Defense Medal for Meritorious Civilian Service, the NGA Meritorious Civilian Service Medal, and the Canadian Chief of Defense Intelligence Medallion.

Dr. James Revill, Ph.D. ( https://unidir.org/staff/james-revill ) is the Head of the Weapons of Mass Destruction (WMD) and Space Security Program, at the UN Institute for Disarmament Research (UNIDIR). Dr. Revill’s research interests focus on the evolution of the chemical and biological weapons and he has published widely in these areas. He was previously a Research Fellow with the Harvard Sussex Program at the Science Policy Research Unit, University of Sussex and completed research fellowships with the Landau Network Volta Center in Italy and the Bradford Disarmament Research Centre in the UK. Dr. Revill holds a Ph.D. focused on the evolution of the Biological Weapons Convention from the University of Bradford, UK. Dr. Revill’s areas of expertise include biological weapons, biosecurity, bioterrorism, chemical weapons, chemical terrorism, chemical weapons convention, compliance, verification, and improvised explosive devices.